Reviva Pharmaceuticals Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Reviva Pharmaceuticals Holdings, Inc.
Small cap biopharma firm Reviva Pharmaceuticals reported intriguing Phase III results for its schizophrenia candidate brilaroxazine that are at least on par with Karuna’s closely watched drug.
Pharma and the US biotech will target key regulators of cellular metabolism with focus on immune and neurological disorders. Royalty Pharma buys portion of PTC’s royalty rights to risdiplam, under development at Roche.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Medtronic appoints new CFO; EndoChoice elevates William Enquist to chairman post; Andrew Bindman named new Agency for Healthcare Research and Quality director; Nexstim seeks new permanent CEO.
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Reviva Pharmaceuticals, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.